Macrophage targeted theranostics as personalized nanomedicine strategies for inflammatory diseases

Theranostics

Volumn 5, Issue 2, 2015, Pages 150-172

  Patel, Sravan Kumar ^a   Janjic, Jelena M ^a  

^a DUQUESNE UNIVERSITY   (United States)

Author keywords

Inflammation; Macrophages; Phenotype; Photodynamic therapy and photothermal therapy; Theranostics

Indexed keywords

AMINOLEVULINIC ACID; CELL ADHESION MOLECULE; CYCLOOXYGENASE 2; D SR 16; DEXTRAN; L SR 15; MYELOID RELATED PROTEIN 14; MYELOID RELATED PROTEIN 8; PHOTOSENSITIZING AGENT; PREDNISOLONE SODIUM PHOSPHATE; PROTEIN S 100; REACTIVE OXYGEN METABOLITE; TALAPORFIN; TUMOR NECROSIS FACTOR ALPHA; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; FLUORESCENCE IMAGING; FLUORINE NUCLEAR MAGNETIC RESONANCE; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; MACROPHAGE; MOLECULAR IMAGING; MULTIMODAL IMAGING; NANOMEDICINE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHENOTYPE; PHOTODYNAMIC THERAPY; PHOTOTHERAPY; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; RHEUMATOID ARTHRITIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TARGET CELL; THERANOSTICS; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; IMMUNOLOGY; PERSONALIZED MEDICINE; PROCEDURES;

DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; MACROPHAGES; NANOMEDICINE; PRECISION MEDICINE;

EID: 84924289808     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.9476     Document Type: Review

References (160)

1. Pene F, Courtine E, Cariou A, Mira JP. Toward theragnostics. Critical care medicine. 2009; 37: S50-8.
2. Rai P, Mallidi S, Zheng X, Rahmanzadeh R, Mir Y, Elrington S, et al. Development and applications of photo-triggered theranostic agents. Advanced drug delivery reviews. 2010; 62: 1094-124.
3. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Advanced drug delivery reviews. 2012; 64: 1394-416.
4. Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Advanced drug delivery reviews. 2010; 62: 1052-63.
5. Couvreur P. Nanoparticles in drug delivery: past, present and future. Advanced drug delivery reviews. 2013; 65: 21-3.
6. Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. Journal of Controlled Release. 2008; 126: 187-204.
7. Choi R, Yang J, Choi J, Lim EK, Kim E, Suh JS, et al. Thiolated dextran-coated gold nanorods for photothermal ablation of inflammatory macrophages. Langmuir: the ACS journal of surfaces and colloids. 2010; 26: 17520-7.
8. Boncel S, Muller KH, Skepper JN, Walczak KZ, Koziol KK. Tunable chemistry and morphology of multi-wall carbon nanotubes as a route to non-toxic, theranostic systems. Biomaterials. 2011; 32: 7677-86.
9. Kosuge H, Sherlock SP, Kitagawa T, Dash R, Robinson JT, Dai H, et al. Near infrared imaging and photothermal ablation of vascular inflammation using single-walled carbon nanotubes. Journal of the American Heart Association. 2012; 1: e002568.
10. Swindell WR, Xing X, Stuart PE, Chen CS, Aphale A, Nair RP, et al. Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis. PloS one. 2012; 7: e34594.
11. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. British medical bulletin. 2000; 56: 1054-70.
12. Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. European heart journal. 2009; 30: 426-35.
13. Lindberg J, af Klint E, Ulfgren AK, Stark A, Andersson T, Nilsson P, et al. Variability in synovial inflammation in rheumatoid arthritis investigated by microarray technology. Arthritis research & therapy. 2006; 8: R47.
14. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? The Lancet. 2001; 357: 539-45.
15. Libby P. Inflammation in atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology. 2012; 32: 2045-51.
16. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiology of aging. 2000; 21: 383-421.
17. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell. 2010; 140: 784-90.
18. [Internet] PR Newswire: Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate. GBI Research, 2011. http://www.prnewswire.com/news-releases/anti-inflammatory-therapeutics-market-to-2017---respiratory-diseases-and-arthritis-continue-to-dominate-132437538.html.
19. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Advanced drug delivery reviews. 2011; 63: 136-51.
20. Medzhitov R. Inflammation 2010: new adventures of an old flame. Cell. 2010; 140: 771-6.
21. Nathan C. Points of control in inflammation. Nature. 2002; 420: 846-52.
22. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2007; 21: 325-32.
23. Fujiwara N, Kobayashi K. Macrophages in inflammation. Current Drug Targets-Inflammation & Allergy. 2005; 4: 281-6.
24. Pollard JW. Trophic macrophages in development and disease. Nature Reviews Immunology. 2009; 9: 259-70.
25. Hasan DM, Mahaney KB, Magnotta VA, Kung DK, Lawton MT, Hashimoto T, et al. Macrophage imaging within human cerebral aneurysms wall using ferumoxytol-enhanced MRI: a pilot study. Arteriosclerosis, thrombosis, and vascular biology. 2012; 32: 1032-8.
26. Petry KG, Boiziau C, Dousset V, Brochet B. Magnetic resonance imaging of human brain macrophage infiltration. Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics. 2007; 4: 434-42.
27. Tang TY, Howarth SP, Miller SR, Graves MJ, Patterson AJ, JM UK-I, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide- enhanced magnetic resonance imaging in carotid disease. Journal of the American College of Cardiology. 2009; 53: 2039-50.
28. Barrera P, Blom A, Van Lent PL, Van Bloois L, Beijnen JH, Van Rooijen N, et al. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis & Rheumatism. 2000; 43: 1951-9.
29. Young L, Katrib A, Cuello C, Vollmer-Conna U, Bertouch JV, Roberts-Thomson PJ, et al. Effects of intraarticular glucocorticoids on macrophage infiltration and mediators of joint damage in osteoarthritis synovial membranes: Findings in a double-blind, placebo-controlled study. Arthritis & Rheumatism. 2001; 44: 343-50.
30. Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis and rheumatism. 2005; 52: 61-72.
31. Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Annals of the rheumatic diseases. 2004; 63: 1344-6.
32. Szefler S, Leung D. Glucocorticoid-resistant asthma: pathogenesis and clinical implications for management. European Respiratory Journal. 1997; 10: 1640-7.
33. Burnett SH, Kershen EJ, Zhang J, Zeng L, Straley SC, Kaplan AM, et al. Conditional macrophage ablation in transgenic mice expressing a Fas-based suicide gene. Journal of leukocyte biology. 2004; 75: 612-23.
34. Cailhier JF, Partolina M, Vuthoori S, Wu S, Ko K, Watson S, et al. Conditional macrophage ablation demonstrates that resident macrophages initiate acute peritoneal inflammation. The Journal of Immunology. 2005; 174: 2336-42.
35. Mirza R, DiPietro LA, Koh TJ. Selective and specific macrophage ablation is detrimental to wound healing in mice. The American journal of pathology. 2009; 175: 2454-62.
36. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nature reviews Immunology. 2011; 11: 723-37.
37. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science. 2010; 327: 656-61.
38. van Ravenswaay Claasen H, Kluin PM, Fleuren G. Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. Laboratory investigation. 1992; 67: 166-74.
39. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008; 454: 428-35.
40. Kinne RW, Stuhlmuller B, Burmester GR. Cells of the synovium in rheumatoid arthritis. Macrophages. Arthritis research & therapy. 2007; 9: 224.
41. Tesch G. Role of macrophages in complications of type 2 diabetes. Clinical and Experimental Pharmacology and Physiology. 2007; 34: 1016-9.
42. Glass C. The macrophage foam cell as a target for therapeutic intervention. Nat Med. 2002; 8: 1235-42.
43. Baay M, Brouwer A, Pauwels P, Peeters M, Lardon F. Tumor cells and tumor- associated macrophages: secreted proteins as potential targets for therapy. Clinical & developmental immunology. 2011; 2011: 565187.
44. Melgert BN. Macrophage Heterogeneity in Respiratory Diseases. Mediators of Inflammation. 2013; 2013: 769214.
45. Gate D, Rezai-Zadeh K, Jodry D, Rentsendorj A, Town T. Macrophages in Alzheimer's disease: the blood-borne identity. Journal of neural transmission. 2010; 117: 961-70.
46. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. The Journal of clinical investigation. 2012; 122: 787-95.
47. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nature Reviews Immunology. 2008; 8: 958-69.
48. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunology today. 1992; 13: 265-70.
49. Gui T, Shimokado A, Sun Y, Akasaka T, Muragaki Y. Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery. Mediators of inflammation. 2012; 2012: 1-14.
50. Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester G-R. Macrophages in rheumatoid arthritis. Arthritis research. 2000; 2: 189-202.
51. Trivedi RA, JM UK-I, Graves MJ, Cross JJ, Horsley J, Goddard MJ, et al. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke; a journal of cerebral circulation. 2004; 35: 1631-5.
52. Trivedi RA, Mallawarachi C, Jean-Marie U, Graves MJ, Horsley J, Goddard MJ, et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arteriosclerosis, thrombosis, and vascular biology. 2006; 26: 1601-6.
53. Gent YY, Voskuyl AE, Kloet RW, van Schaardenburg D, Hoekstra OS, Dijkmans BA, et al. Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: findings of a prospective pilot study. Arthritis and rheumatism. 2012; 64: 62-6.
54. Brochet B, Deloire M, Touil T, Anne O, Caille J, Dousset V, et al. Early macrophage MRI of inflammatory lesions predicts lesion severity and disease development in relapsing EAE. Neuroimage. 2006; 32: 266-74.
55. Dobrucki LW, Sinusas AJ. PET and SPECT in cardiovascular molecular imaging. Nature Reviews Cardiology. 2009; 7: 38-47.
56. Chacko AM, Hood ED, Zern BJ, Muzykantov VR. Targeted nanocarriers for imaging and therapy of vascular inflammation. Current opinion in colloid & interface science. 2011; 16: 215-27.
57. Moses WW. Fundamental limits of spatial resolution in PET. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. 2011; 648: S236-S40.
58. Srinivas M, Heerschap A, Ahrens ET, Figdor CG, Vries IJM. 19F MRI for quantitative in vivo cell tracking. Trends in biotechnology. 2010; 28: 363-70.
59. Geraldes CF, Laurent S. Classification and basic properties of contrast agents for magnetic resonance imaging. Contrast media & molecular imaging. 2009; 4: 1-23.
60. Fass L. Imaging and cancer: a review. Molecular oncology. 2008; 2: 115-52.
61. Kim J, An H, Rieter W, Esserman D, Taylor-Pashow K, Sartor R, et al. Multimodal optical and Gd-based nanoparticles for imaging in inflammatory arthritis. Clinical and experimental rheumatology. 2009; 27: 580-6.
62. Dousset V, Brochet B, Deloire M, Lagoarde L, Barroso B, Caille J-M, et al. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. American journal of neuroradiology. 2006; 27: 1000-5.
63. Wolters M, Mohades SG, Hackeng TM, Post MJ, Kooi ME, Backes WH. Clinical Perspectives of Hybrid Proton-Fluorine Magnetic Resonance Imaging and Spectroscopy. Investigative radiology. 2013; 48 :341-50.
64. Srinivas M, Boehm-Sturm P, Figdor CG, de Vries IJ, Hoehn M. Labeling cells for in vivo tracking using 19F MRI. Biomaterials. 2012; 33 :8830-40.
65. Janjic JM, Ahrens ET. Fluorine-containing nanoemulsions for MRI cell tracking. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2009; 1: 492-501.
66. Schmid F, Höltke C, Parker D, Faber C. Boosting 19F MRI-SNR efficient detection of paramagnetic contrast agents using ultrafast sequences. Magnetic Resonance in Medicine. 2013; 69 :1056-62.
67. Weibel S, Basse-Luesebrink TC, Hess M, Hofmann E, Seubert C, Langbein-Laugwitz J, et al. Imaging of Intratumoral Inflammation during Oncolytic Virotherapy of Tumors by (19)F-Magnetic Resonance Imaging (MRI). PloS one. 2013; 8: e56317.
68. Srinivas M, Morel PA, Ernst LA, Laidlaw DH, Ahrens ET. Fluorine-19 MRI for visualization and quantification of cell migration in a diabetes model. Magnetic Resonance in Medicine. 2007; 58: 725-34.
69. Caruthers SD, Cyrus T, Winter PM, Wickline SA, Lanza GM. Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2009; 1: 311-23.
70. Lanza GM, Winter PM, Caruthers SD, Hughes MS, Hu G, Schmieder AH, et al. Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis. 2010; 13: 189-202.
71. Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, et al. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology. 2006; 26: 2103-9.
72. Balducci A, Wen Y, Zhang Y, Helfer BM, Hitchens TK, Meng WS, et al. A novel probe for the non-invasive detection of tumor-associated inflammation. OncoImmunology. 2013; 2:e23034.
73. Balducci A, Helfer BM, Ahrens ET, O'Hanlon CF, Wesa AK. Visualizing arthritic inflammation and therapeutic response by fluorine-19 magnetic resonance imaging (19F MRI). Journal of Inflammation. 2012; 9: 1-10.
74. Ebner B, Behm P, Jacoby C, Burghoff S, French BA, Schrader J, et al. Early Assessment of Pulmonary Inflammation by 19F MRI In VivoCLINICAL PERSPECTIVE. Circulation: Cardiovascular Imaging. 2010; 3: 202-10.
75. Hitchens TK, Ye Q, Eytan DF, Janjic JM, Ahrens ET, Ho C. 19F MRI detection of acute allograft rejection with in vivo perfluorocarbon labeling of immune cells. Magnetic Resonance in Medicine. 2011; 65: 1144-53.
76. Kadayakkara DK, Ranganathan S, Young W-B, Ahrens ET. Assaying macrophage activity in a murine model of inflammatory bowel disease using fluorine- 19 MRI. Laboratory Investigation. 2012; 92: 636-45.
77. [Internet] Celsense New Release: The First Patient Treated Using Celsense MRI Cell Tracking Technology; 2013. http://www.celsense.com/april11_first_patient.html.
78. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation. 2008; 117: 379-87.
79. Morishige K, Kacher DF, Libby P, Josephson L, Ganz P, Weissleder R, et al. High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation. 2010; 122: 1707-15.
80. Nahrendorf M, Waterman P, Thurber G, Groves K, Rajopadhye M, Panizzi P, et al. Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors. Arteriosclerosis, thrombosis, and vascular biology. 2009; 29: 1444-51.
81. Jarrett BR, Correa C, Ma KL, Louie AY. In vivo mapping of vascular inflammation using multimodal imaging. PloS one. 2010; 5: e13254.
82. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nature medicine. 2003; 9: 123-8.
83. Frangioni JV. In vivo near-infrared fluorescence imaging. Current opinion in chemical biology. 2003; 7: 626-34.
84. Luo S, Zhang E, Su Y, Cheng T, Shi C. A review of NIR dyes in cancer targeting and imaging. Biomaterials. 2011; 32: 7127-38.
85. Demchenko AP, Mély Y, Duportail G, Klymchenko AS. Monitoring biophysical properties of lipid membranes by environment-sensitive fluorescent probes. Biophysical journal. 2009; 96: 3461-70.
86. Kosaka N, Ogawa M, Choyke PL, Kobayashi H. Clinical implications of near-infrared fluorescence imaging in cancer. Future Oncology. 2009; 5: 1501-11.
87. Chellat F, Merhi Y, Moreau A, Yahia L. Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials. 2005; 26: 7260-75.
88. Lim YT, Cho MY, Choi BS, Noh Y-W, Chung BH. Diagnosis and therapy of macrophage cells using dextran-coated near-infrared responsive hollow-type gold nanoparticles. Nanotechnology. 2008; 19: 375105.
89. Jain S, Amiji M. Tuftsin-Modified Alginate Nanoparticles as a Noncondensing Macrophage-Targeted DNA Delivery System. Biomacromolecules. 2012; 13: 1074-85.
90. Kelly C, Jefferies C, Cryan SA. Targeted liposomal drug delivery to monocytes and macrophages. Journal of drug delivery. 2011; 2011: 727241.
91. Choi J, Kim HY, Ju EJ, Jung J, Park J, Chung HK, et al. Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. Biomaterials. 2012; 33: 4195-203.
92. Choi M-R, Stanton-Maxey KJ, Stanley JK, Levin CS, Bardhan R, Akin D, et al. A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. Nano letters. 2007; 7: 3759-65.
93. Verheye S, Martinet W, Kockx MM, Knaapen MW, Salu K, Timmermans J-P, et al. Selective clearance of macrophages in atherosclerotic plaques by autophagy. Journal of the American College of Cardiology. 2007; 49: 706-15.
94. Danenberg HD, Fishbein I, Gao J, Mönkkönen J, Reich R, Gati I, et al. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation. 2002; 106: 599-605.
95. Zeisberger S, Odermatt B, Marty C, Zehnder-Fjällman A, Ballmer-Hofer K, Schwendener R. Clodronate-liposome-mediated depletion of tumour- associated macrophages: a new and highly effective antiangiogenic therapy approach. British journal of cancer. 2006; 95: 272-81.
96. Celli JP, Spring BQ, Rizvi I, Evans CL, Samkoe KS, Verma S, et al. Imaging and photodynamic therapy: mechanisms, monitoring and optimization. Chemical reviews. 2010; 110: 2795-838.
97. Allison RR, Downie GH, Cuenca R, Hu X-H, Childs CJH, Sibata CH. Photosensitizers in clinical PDT. Photodiagnosis and Photodynamic Therapy. 2004; 1: 27-42.
98. Kirdaite G, Lange N, Busso N, Van Den Bergh H, Kucera P, So A. Protoporphyrin IX photodynamic therapy for synovitis. Arthritis & Rheumatism. 2002; 46: 1371-8.
99. Peng C, Li Y, Liang H, Cheng J, Li Q, Sun X, et al. Detection and photodynamic therapy of inflamed atherosclerotic plaques in the carotid artery of rabbits. Journal of Photochemistry and Photobiology B: Biology. 2011; 102: 26-31.
100. Fotinos N, Campo MA, Popowycz F, Gurny R, Lange N. 5-Aminolevulinic Acid Derivatives in Photomedicine: Characteristics, Application and Perspectives. Photochemistry and photobiology. 2006; 82: 994-1015.
101. Schmitt F, Lagopoulos L, Käuper P, Rossi N, Busso N, Barge J, et al. Chitosan- based nanogels for selective delivery of photosensitizers to macrophages and improved retention in and therapy of articular joints. Journal of Controlled Release. 2010; 144: 242-50.
102. McCarthy JR, Korngold E, Weissleder R, Jaffer FA. A Light-Activated Theranostic Nanoagent for Targeted Macrophage Ablation in Inflammatory Atherosclerosis. Small. 2010; 6: 2041-9.
103. Tong L, Cheng J-X. Gold nanorod-mediated photothermolysis induces apoptosis of macrophages via damage of mitochondria. Nanomedicine. 2009; 4: 265-76.
104. McCarthy JR, Jaffer FA, Weissleder R. A macrophage-targeted theranostic nanoparticle for biomedical applications. Small. 2006; 2: 983-7.
105. Tassa C, Shaw SY, Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Accounts of chemical research. 2011; 44: 842-52.
106. Shon S-M, Choi Y, Kim J-Y, Lee DK, Park J-Y, Schellingerhout D, et al. Photodynamic Therapy Using a Protease-Mediated Theranostic Agent Reduces Cathepsin-B Activity in Mouse Atheromata In Vivo. Arteriosclerosis, thrombosis, and vascular biology. 2013; 33: 1360-5.
107. Choi Y, Weissleder R, Tung C-H. Selective antitumor effect of novel protease- mediated photodynamic agent. Cancer research. 2006; 66: 7225-9.
108. Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S. Cathepsin cysteine proteases in cardiovascular disease. The FASEB Journal. 2007; 21: 3029-41.
109. Gabriel D, Busso N, So A, van den Bergh H, Gurny R, Lange N. Thrombin- sensitive photodynamic agents: a novel strategy for selective synovectomy in rheumatoid arthritis. Journal of controlled release: official journal of the Controlled Release Society. 2009; 138: 225-34.
110. Gabriel D, Lange N, Chobaz-Peclat V, Zuluaga MF, Gurny R, van den Bergh H, et al. Thrombin-sensitive dual fluorescence imaging and therapeutic agent for detection and treatment of synovial inflammation in murine rheumatoid arthritis. Journal of controlled release: official journal of the Controlled Release Society. 2012; 163: 178-86.
111. Spernyak JA, White III WH, Ethirajan M, Patel NJ, Goswami L, Chen Y, et al. Hexylether derivative of pyropheophorbide-a (HPPH) on conjugating with 3gadolinium (III) aminobenzyldiethylenetriaminepentaacetic acid shows potential for in vivo tumor imaging (MR, fluorescence) and photodynamic therapy. Bioconjugate chemistry. 2010; 21: 828-35.
112. Ma LL, Feldman MD, Tam JM, Paranjape AS, Cheruku KK, Larson TA, et al. Small multifunctional nanoclusters (nanoroses) for targeted cellular imaging and therapy. ACS nano. 2009; 3: 2686-96.
113. Tong L, Wei Q, Wei A, Cheng JX. Gold Nanorods as Contrast Agents for Biological Imaging: Optical Properties, Surface Conjugation and Photothermal Effectst. Photochemistry and photobiology. 2009; 85: 21-32.
114. Pissuwan D, Valenzuela SM, Killingsworth MC, Xu X, Cortie MB. Targeted destruction of murine macrophage cells with bioconjugated gold nanorods. Journal of Nanoparticle Research. 2007; 9: 1109-24.
115. Robinson JT, Welsher K, Tabakman SM, Sherlock SP, Wang H, Luong R, et al. High performance in vivo near-IR (> 1 μm) imaging and photothermal cancer therapy with carbon nanotubes. Nano research. 2010; 3: 779-93.
116. Shvedova AA, Kisin ER, Mercer R, Murray AR, Johnson VJ, Potapovich AI, et al. Unusual inflammatory and fibrogenic pulmonary responses to single- walled carbon nanotubes in mice. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2005; 289: L698-L708.
117. Tatar O, Adam A, Shinoda K, Yoeruek E, Szurman P, Bopp S, et al. Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration. Retina. 2007; 27: 713-23.
118. Firczuk M, Nowis D, Golab J. PDT-induced inflammatory and host responses. Photochemical & Photobiological Sciences. 2011; 10: 653-63.
119. Chakravarthy KV, Davidson BA, Helinski JD, Ding H, Law WC, Yong KT, et al. Doxorubicin-conjugated quantum dots to target alveolar macrophages and inflammation. Nanomedicine. 2011; 7: 88-96.
120. Kluza E, Yeo SY, Schmid S, van der Schaft DW, Boekhoven RW, Schiffelers RM, et al. Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. Journal of controlled release: official journal of the Controlled Release Society. 2011; 151: 10-7.
121. Ragheb RR, Kim D, Bandyopadhyay A, Chahboune H, Bulutoglu B, Ezeldein H, et al. Induced clustered nanoconfinement of superparamagnetic iron oxide in biodegradable nanoparticles enhances transverse relaxivity for targeted theranostics. Magnetic resonance in medicine. Magnetic Resonance in Medicine. 2013; 70: 1748-60.
122. Kluza E, Heisen M, Schmid S, van der Schaft DW, Schiffelers RM, Storm G, et al. Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids. Angiogenesis. 2011; 14: 143-53.
123. Hofkens W, Storm G, van den Berg W, van Lent P. Inhibition of M1 macrophage activation in favour of M2 differentiation by liposomal targeting of glucocorticoids to the synovial lining during experimental arthritis. Annals of the rheumatic diseases. 2011; 70: A40-A45.
124. Tracy EC, Bowman MJ, Henderson BW, Baumann H. Interleukin-1alpha is the major alarmin of lung epithelial cells released during photodynamic therapy to induce inflammatory mediators in fibroblasts. British journal of cancer. 2012; 107: 1534-46.
125. Harel-Adar T, Mordechai TB, Amsalem Y, Feinberg MS, Leor J, Cohen S. Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proceedings of the National Academy of Sciences. 2011; 108: 1827-32.
126. Siglienti I, Bendszus M, Kleinschnitz C, Stoll G. Cytokine profile of iron-laden macrophages: implications for cellular magnetic resonance imaging. Journal of neuroimmunology. 2006; 173: 166-73.
127. Fraccarollo D, Galuppo P, Bauersachs J. Novel therapeutic approaches to post-infarction remodelling. Cardiovascular research. 2012; 94: 293-303.
128. Nakanishi Y, Nakatsuji M, Seno H, Ishizu S, Akitake-Kawano R, Kanda K, et al. COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis. 2011; 32: 1333-9.
129. Shen J, Chelvam V, Cresswell G, Low PS. Use of Folate-Conjugated Imaging Agents To Target Alternatively Activated Macrophages in a Murine Model of Asthma. Molecular pharmaceutics. 2013; 10: 1918-27.
130. Melancon MP, Lu W, Huang Q, Thapa P, Zhou D, Ng C, et al. Targeted imaging of tumor-associated M2 macrophages using a macromolecular contrast agent PG-Gd-NIR813. Biomaterials. 2010; 31: 6567-73.
131. Stüve O, Bennett JL. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri®) in inflammatory diseases. CNS drug reviews. 2007; 13: 79-95.
132. Melgarejo E, Medina Má, Sánchez-Jiménez F, Urdiales JL. Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. The international journal of biochemistry & cell biology. 2009; 41: 998-1001.
133. Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, Courties G, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nature biotechnology. 2011; 29: 1005-10.
134. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009; 325: 612-6.
135. Majmudar MD, Yoo J, Keliher EJ, Truelove JJ, Iwamoto Y, Sena B, et al. Polymeric Nanoparticle PET/MR Imaging Allows Macrophage Detection in Atherosclerotic PlaquesNovelty and Significance. Circulation research. 2013; 112: 755-61.
136. Abedini F, Hosseinkhani H, Ismail M, Domb AJ, Omar AR, Chong PP, et al. Cationized dextran nanoparticle-encapsulated CXCR4-siRNA enhanced correlation between CXCR4 expression and serum alkaline phosphatase in a mouse model of colorectal cancer. International journal of nanomedicine. 2012; 7: 4159-68.
137. Tlaxca JL, Rychak JJ, Ernst PB, Konkalmatt PR, Shevchenko TI, Pizzaro TT, et al. Ultrasound-based molecular imaging and specific gene delivery to mesenteric vasculature by endothelial adhesion molecule targeted microbubbles in a mouse model of Crohn's disease. Journal of controlled release: official journal of the Controlled Release Society. 2013; 165: 216-25.
138. Esposito E, Cuzzocrea S. TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Current medicinal chemistry. 2009; 16: 3152-67.
139. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. Medscape General Medicine. 2006; 8: 25.
140. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. Journal of dermatological treatment. 2004; 15: 280-94.
141. Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature. 2009; 458: 1180-4.
142. Yin L, Song Z, Qu Q, Kim KH, Zheng N, Yao C, et al. Supramolecular Self-Assembled Nanoparticles Mediate Oral Delivery of Therapeutic TNF-alpha siRNA against Systemic Inflammation. Angewandte Chemie International English. 2013; 52:5757-61.
143. Komano Y, Yagi N, Onoue I, Kaneko K, Miyasaka N, Nanki T. Arthritic joint-targeting small interfering RNA-encapsulated liposome: implication for treatment strategy for rheumatoid arthritis. The Journal of pharmacology and experimental therapeutics. 2012; 340: 109-13.
144. Koki A, Khan NK, Woerner BM, Dannenberg A, Olson L, Seibert K, et al. Cyclooxygenase-2 in human pathological disease. Advances in Experimental Medicine and Biology. 2002; 507: 177-84.
145. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, et al. Cyclooxygenase- 2 is instrumental in Parkinson's disease neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100: 5473-8.
146. Wang K, Tarakji K, Zhou Z, Zhang M, Forudi F, Zhou X, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model. Journal of cardiovascular pharmacology. 2005; 45: 61-7.
147. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. British Medical Journal. 2002; 325: 619.
148. Gallicchio M, Rosa A, Dianzani C, Brucato L, Benetti E, Collino M, et al. Celecoxib decreases expression of the adhesion molecules ICAM-1 and VCAM-1 in a colon cancer cell line (HT29). British journal of pharmacology. 2008; 153: 870-8.
149. Venkatesan P, Puvvada N, Dash R, Prashanth Kumar B, Sarkar D, Azab B, et al. The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer. Biomaterials. 2011; 32: 3794-806.
150. Uddin MJ, Crews BC, Blobaum AL, Kingsley PJ, Gorden DL, McIntyre JO, et al. Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer research. 2010; 70: 3618-27.
151. Uddin MJ, Crews BC, Ghebreselasie K, Huda I, Kingsley PJ, Ansari MS, et al. Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer. Cancer Prevention Research. 2011; 4: 1536-45.
152. Mikhaylova M, Stasinopoulos I, Kato Y, Artemov D, Bhujwalla Z. Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA. Cancer gene therapy. 2008; 16: 217-26.
153. Patel SK, Zhang Y, Pollock JA, Janjic JM. Cyclooxgenase-2 Inhibiting Perfluoropoly (Ethylene Glycol) Ether Theranostic Nanoemulsions-In Vitro Study. PloS one. 2013; 8: e55802.
154. Lee D, Khaja S, Velasquez-Castano JC, Dasari M, Sun C, Petros J, et al. In vivo imaging of hydrogen peroxide with chemiluminescent nanoparticles. Nature materials. 2007; 6: 765-9.
155. Lee I-J, Hwang O, Yoo D-H, Khang G-S, Lee D-W. Detection of Hydrogen Peroxide in vitro and in vivo Using Peroxalate Chemiluminescent Micelles. Bulletin of the Korean Chemical Society. 2011; 32: 2187-92.
156. Cho S, Hwang O, Lee I, Lee G, Yoo D, Khang G, et al. Chemiluminescent and Antioxidant Micelles as Theranostic Agents for Hydrogen Peroxide Associated- Inflammatory Diseases. Advanced Functional Materials. 2012; 22: 4038-43.
157. Park H, Kim S, Kim S, Song Y, Seung K, Hong D, et al. Antioxidant and anti- inflammatory activities of hydroxybenzyl alcohol releasing biodegradable polyoxalate nanoparticles. Biomacromolecules. 2010; 11: 2103-8.
158. Tu C, Osborne EA, Louie AY. Activatable T(1) and T(2) magnetic resonance imaging contrast agents. Annals of biomedical engineering. 2011; 39: 1335-48.
159. Maiseyeu A, Badgeley MA, Kampfrath T, Mihai G, Deiuliis JA, Liu C, et al. In vivo targeting of inflammation-associated myeloid-related protein 8/14 via gadolinium immunonanoparticles. Arteriosclerosis, thrombosis, and vascular biology. 2012; 32: 962-70.
160. Schellekens H. Follow-on biologics: challenges of the 'next generation'. Nephrology Dialysis Transplantation. 2005; 20: iv31-iv6.